The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

The incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir compared with daily oral emtricitabine-tenofovir disoproxil fumarate.

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the virus.

A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

FOX 5 spoke exclusively with a participant in a study for a new injectable drug to prevent HIV. Emory University medical ...

Lenacapavir, an injectable drug for HIV prevention, is praised as a potential game-changer and offers hope for those who find daily oral medications challenging. The drug requires administration ...

"Currently, there is no therapeutic cure for HIV," Sheryl Zwerski, who holds a Doctor of Nursing Practice and directs the Prevention Sciences Program at the National Institute of Allergy and ...

The lenacapavir group also received 2 initial ... highlighted the following components of the study’s findings to Medical News Today: “There were only two incident cases of HIV infection ...